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Abstract
Background: Cardiovascular diseases are the leading cause of death in Lebanon and Qatar. When lifestyle
modifications prove insufficient, medication becomes a cornerstone in controlling such diseases and saving lives.
Price, availability, and affordability hinder the equitable access to medicines. The study aimed to assess prices,
availability, and affordability of essential cardiovascular disease medicines in relation to pricing strategies in Qatar
and Lebanon.
Methods: A cross-sectional survey using a variant of the World Health Organization and Health Action International
(WHO/HAI) methodology as outlined in “Measuring medicine prices, availability, affordability and price components”
(2008), second edition, was adopted. Prices and availability of 27 cardiovascular medicines were collected from
public and private dispensing outlets. For international comparison, prices were adjusted to purchasing power
parity. Data was analyzed across multiple sectors, within and across countries.
Results: A total of 15 public and private outlets were surveyed in each country. Prices were more uniform in Qatar
than in Lebanon. In the public sector, medicines were free-of-charge in Lebanon and priced lower than the
international reference prices in Qatar. The ratio of medicine unit price to international reference price in the private
sectors surveyed are significantly higher than the acceptable threshold of 4. This ratio of originator brands and
lowest priced generics in Qatar were up to two and five times those in Lebanon, respectively, even after adjusting
for purchasing power parity. However, prices of lowest priced generics in the private sector were at least 35%
cheaper in Qatar and 65% cheaper in Lebanon than their comparative originator brands. Medicines were more
available in the private sector in Lebanon than in Qatar, but only the originator brand availability in the public
sector in Qatar exceeded the WHO target of more than 80%. While affordable in the public sector in Qatar, four out
of thirteen medicines exceeded the threshold in all private sectors covered. Hence, only the public sector in Qatar
had a satisfying level of availability and affordability.
Conclusions: Except for the Qatari public sector, medicine prices, availability, and affordability are falling short from
targets. Key policy decisions should be implemented to improve access to medicines.
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Background
Medication is a cornerstone in medical disease manage-
ment and the timely presence and appropriate integra-
tion of medication in a treatment plan for short- and
long-term ailments are crucial. This is quite evident in
the life-long treatment of non-communicable diseases
(NCD) such as cardiovascular diseases (CVD) when
first-line lifestyle modifications [1–3] are proven in-
appropriate and unsuccessful. According to the latest
WHO global disease burden report (2014), NCD are the
leading cause of death worldwide of which CVD
accounted for almost half of the death cases. Similar
high figures were observed in the Eastern Mediterranean
Regional Office of the WHO (EMRO) [4] as well where
risk factors for CVD and non-adherence to primary
management guidelines are highly prevalent [5–7].
Therefore, ensuring a sustainable access to medicines
is deemed indispensable. Access can be defined by the
ability of citizens to reach and use pharmaceuticals that
are of good quality and affordable, when needed [8]. The
price of medicines was one of the barriers to such con-
sistent access [9]. Furthermore, data from few small-
scale studies had shown that prices in low-income coun-
tries were higher than in richer countries. Several non-
governmental organizations (NGO) and WHO
acknowledge that to improve the availability and the af-
fordability of essential medicines, evidence-based na-
tional policies and programs must be developed. Sound
information based on systematic surveys of standard
methodology to evaluate the price and availability of
medicines was lacking. As a result, the WHO/HAI Pro-
ject on Medicine Prices and Availability was established
in 2001. After several provisional surveys, the method-
ology was launched in 2003, and has since been regularly
reviewed to increase its efficiency and transparency [9].
Several middle-eastern countries, e.g., Kuwait, Lebanon,
and Syria, participated in the first version of WHO/HAI
project in 2003, and consequently undertook action to-
wards medicine price reduction and enhancement of
availability based on the survey findings and recommen-
dations [10]. A closer look into two middle-eastern
countries within the EMRO, Qatar and Lebanon, of dif-
ferent economic indicators demonstrated that cardiovas-
cular diseases are the first leading causes of death in
Lebanon and the second in Qatar after road injuries
[11]. Both countries included prevention strategies
against chronic diseases generally and CVD especially in
their national vision and had set future plans to manage
and control the spread of cardiovascular diseases [12–
14]. Moreover, the medicine prices were perceived to be
high in these two countries compared to respective
neighboring countries [15–17]. Considering this evi-
dence, Abdel Rida et al. conducted a narrative review
and document analysis of the pharmaceutical pricing
policies in Qatar and Lebanon [18]. Both Qatar and
Lebanon have implemented similar pharmaceutical pri-
cing policies. External reference pricing (ERP) is one of
the pricing policies adopted by both countries, albeit
with different baskets of reference countries. The basket
of countries to which the prices in each country are
benchmarked vary [19, 20]. In addition to ERP, mark-up
regulations are applied with different schemes along the
pharmaceutical supply chain. While a decree detailing all
the different regressive mark-up1 schemes is available to
the public in Lebanon [21], such detailed scheme is not
available in Qatar. The standardized mark-up is linear
and capped at 44% on all medicine in the private sector.
In addition, Qatar may consider the economic evaluation
of a medicine to set the price if such evaluation or
Health Technology Assessment (HTA) is available at the
time of registration [20]. The prices of generic medicines
are set at fixed lower percentage in comparison to the
price of the originator brand in both countries as per
Appendix. Generic brands are classified according to the
chronological order in which they get registered and
enter the market in both Qatar and Lebanon [19, 20].
The price of the first registered generics is 30 and 35%
lower than their comparative OB available in the market
in Lebanon and Qatar respectively. Additionally, pricing
of generics in Lebanon considers the country of origin in
a pricing strategy and the price variation of different
generic brands within the same category similar to in-
ternal reference pricing used internationally [19, 22].
Lebanon also adopts yet a different markup scheme for
locally manufactured generics [19].
Qatar and Lebanon differ in terms of economic indica-
tors due to the differences in income levels. While Qatar
is a high-income country, Lebanon is an upper-middle
income country. The pharmaceutical sector is a major
subset of the health sector especially with spending on
pharmaceuticals constituting a high percentage of the
total health expenditure [23–25]. In Lebanon, almost
half of the health expenditure is attributed to purchase
of pharmaceuticals [26] while it only constitutes 10.90%
of the total health expenditure in Qatar where most of
the expenditure on health was in the public sector as per
Table 1 below. In the last decade, the public health sec-
tor in Qatar has been expanding to provide high-
standard primary health care services across the state.
The health services are provided for free for Qatari citi-
zens while residents or non-Qatari pay 20% of the total
healthcare bill. The primary health care centers in
Lebanon cover most of the Lebanese territory, however,
1Mark-up: The additional costs to the manufacturer selling price
(MSP) in the form of charges and costs to cover different stages of the
distribution chain including profits, overheads cost, and distribution
fees. Regressive mark-up: lower mark-up for higher priced medicines.
Abdel Rida et al. BMC Health Services Research          (2019) 19:973 Page 2 of 14
due to budget constraints, services are limited in terms
of population coverage, clinical services and pharma-
ceutical products dispensing. If available, medicines are
dispensed free of charge for beneficiaries in the public
primary health centers in Lebanon. Out of an approxi-
mate population of 4.5 million in 2011, only 162,016 pa-
tients had access to chronic non-communicable diseases
medicines from the public sector in Lebanon [17].
The management and control of the spread of CVD
starts with a prevention plan, however, treatment is
equally essential. While acknowledging the efforts of
both countries to implement pricing guideline (e.g.,
benchmarking and mark-up), it is imperative to analyze
the status of essential medicines (i.e. the access to essen-
tial medicines in terms of price, availability, affordability,
and accessibility) aimed at treating CVD which are
highly prevalent. Assessing access to these medicines is
needed in order to achieve optimal adherence to second-
ary prevention measures in treating early stages of CVD,
to minimize complications, hospitalizations, and mortal-
ity, and to control the total cost of diseases management
[23]. Level of access to medication is determined
through the evaluation of prices, availability and afford-
ability of these medicines [32]. Thus far no research has
been conducted in Qatar to investigate whether all es-
sential CVD medicines are available or affordable in the
private or public sector especially after the phased price
cut undertaken by the gulf countries [33]. In this phased
price cut, medicines were classified into five main cat-
egories and the prices within each category were
reviewed and reduced [33]. Similarly, the latest survey
conducted in Lebanon by the WHO/HAI included only
three CVD medicines [17] and was published in 2013
prior to the latest review of pharmaceutical pricing
guidelines at the end of 2014 [21]. The main objective of
the WHO/HAI survey is to collect reliable data related
to prices, availability, and affordability of a specific bas-
ket of medicines and price components added through-
out the supply chain. Given the profile of CVD and the
pharmaceutical pricing containment strategies under-
taken in Qatar and Lebanon as presented above [19–21],
this study was developed to collect data from different
sectors and medicine selling outlets (i.e. community
pharmacies or outpatient pharmacies), in order to per-
mit a better understanding of the current pharmaceut-
ical situation in terms of cardiovascular disease
medicines price, availability, and affordability in both
countries.
Methods
Study methodology overview
Ideally, WHO/HAI methodology is used for a national
survey, or across a state or province in case of large
countries. Data about the medicines’ price, availability
and affordability are collected from up to 4 different sec-
tors. It is recommended to cover at least the capital plus
5 other areas within one-day drive from the capital. In
each area, it is recommended to collect data from 5 out-
lets per sector. In case of an outlet with an availability of
medicines less than 50% of the list surveyed, another
outlet within the same area should be visited. Moreover,
validation visits for 20% of the outlets is recommended.
Lebanon and Qatar have comparable areas, 10,452km2
and 11,610km2, respectively [34]. However, the popula-
tions vary significantly. Lebanon has a population of
more than 5 million, almost double the population of
Qatar with a much higher population density [34]. Ac-
cording to WHO/HAI [9], the selection of the covered
areas should be based on geographical districts around
the country with a minimum population density. The
real retail price paid by the patient is collected in each
sector in local currency. Surveyed outlets should have an
outpatient pharmacy dispensing medicines directly to
the patient. To calculate the affordability, the lowest-
paid unskilled government worker (LPGW) salary is
identified. Affordability is then estimated based the cost
of a full treatment regimen for either acute or chronic
disease in terms of the number of the days’ wages for-
gone by the LPGW to purchase the treatment. The out-
let sampling is conducted in a randomized and
systematic manner to ensure enough coverage. The se-
lection of outlets is related to the demographics of a
given area surveyed. The purpose is to randomly choose
a region and consequently outlets that comply with the
criteria set by WHO/HAI e.g.: minimum population and
Table 1 Qatar and Lebanon economic indicators and
demographics
Qatar Lebanon
GDP (bn) $164.64 $47.08
Population (mn) 2.58a 6.24b
Citizens (mn) 0.313c 4.751b
GDP Per Capita (35) $73,653 $8,047
Health Expenditure (bn) $4.82 $3.34
Public Health Expenditure (bn) $4.10 $1.59
Private Health Expenditure (bn) $0.72 $1.75
Pharmaceutical Sales (bn) $0.52 $1.64
Pharmaceutical Sales, % of Health Expenditure 10.90 49.00
Per Capita Spending on Pharmaceuticals $234 $280
Spending on Originator Pharmaceuticals (mn) $360.0 $800.0
Spending on Generic Pharmaceuticals (mn) $110.0 $490.0
Source:
World Bank [27]
Business Monitor International (BMI) [26]
Business Monitor International [28]
aMinistry of Development Planning and Statistics (mdps) [29]
bCentral Intelligence Agency (CIA) [30]
cSnoj [31]
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distance from the capital. The list of surveyed medicines
can include up to 50 medicines while the affordability
can be calculated for up to 22. For each medicine, data
about the originator brand (OB) and lowest-priced gen-
eric (LPG) available at the outlet are collected. The sec-
ond edition of Measuring medicine prices, availability,
affordability, and price components (2008) of WHO/HAI
methodology was adopted with some variations in terms
of number of areas covered in Qatar; facility number per
sector and area; back-up and validation visits. This was
due to the inherent geographical and demographic char-
acteristics of the countries surveyed as mentioned above
especially in Qatar and to the limited resources available
to the researchers.
Study design
The study was a cross-sectional observational and com-
parative survey, carried out in two different countries:
Qatar and Lebanon. The main areas surveyed were the
capital cities in both countries (Doha and Beirut) in
addition to other administrative areas within one-hour
drive from each capital. In Lebanon, the population is
dispersed across the country. However, Qatar has a cen-
tralized population density around fewer main cities or
municipalities. As such, the availability and types of
healthcare services and facilities in both countries are re-
flective of the demographic profiles. The 1 + 5 target was
achievable in Lebanon due to its multiple population
centers [9]. However, the centralized population in
Qatar limited our surveyed areas to 1 + 4.
Population sampling and data collection
Data were collected from public health care centers
(Public Sector), private pharmacies (Private Sector) in
both countries and private hospitals or clinics (Other
Sector) exclusively in Qatar between November 2016
and April 2017. No private hospitals/clinics were cov-
ered in Lebanon since none had an outpatient pharma-
ceutical dispensing outlet. In each area surveyed, a
public outpatient health care center was identified, and
thereafter, a proximal private sector facility was selected
within the same region. The medicine outlets surveyed
were contacted and informed of the date, time, and ap-
proximate duration of the visit. One facility per sector
was covered.
In case of an outlet where less than 50% of the sur-
veyed medicines were available, a back-up outlet from
the same sector was visited where possible. Finding a
back-up private community pharmacy in both countries
was possible. However, this was not an option in the
public sector in Qatar given that only one primary
health care center is available per specific area. No valid-
ation visits were conducted. For each medicine, data
about the originator brand (OB) and the lowest-priced
equivalent generic (LPG) available in the outlet at the
time of the visit were collected. Each outlet was visited
once.
Medicine selection
To compile a common list of essential CVD medicines,
the 2014 Lebanese essential medicine list (EML) avail-
able at the time of the study was adopted [35]. This list
was in line with the 18th edition of WHO list [35]. To
compile a common list, the CVD medicines were first
compared to the medicines available in Qatar. As a re-
sult, the list of Lebanese CVD essential medicines was
refined by excluding the medicines that were not avail-
able in Qatar, were not available in level 1 facility, or did
not have an international reference price (IRP) as per
Fig. 1. The 27 common essential CVD medicines
achieved were compared to the latest WHO 19th EML
(Table 2). Given that only 22 medicines can be consid-
ered for affordability calculation as per the WHO/HAI
methodology, only the first line treatment medicines for
the main cardiovascular diseases were included in our
survey. The decision was made after reviewing the latest
cardiovascular disease clinical guidelines [36] and con-
solidated by a meeting with the clinical pharmacy de-
partment in Hamad Medical Corporation (HMC) in
Qatar. The final medicine considered for the affordabil-
ity calculation covered those used for one or more of the
following diseases: angina, arrhythmia, hypertension,
hyperlipidemia, heart failure, and finally antithrombotic
medicines [35]
Outcomes measures
Unit prices of either tablets or capsules in local currency
were recorded. To calculate the median price ratio
(MPR), the unit price were converted to US dollar as per
Oanda [37] then divided per the IRP collected from
International Price Guide (2014) published by Manage-
ment Sciences for Health (MSH) [38] as per the equa-
tion below.
MPR of a specific medicine ¼ median local unit price
international reference unit price
Most of the data collection took place between Au-
gust–November 2016. As the public primary health-
care centers survey in Qatar was surveyed in 2017,
hence the median price ratios for this sector were ad-
justed based on the corresponding year’s consumer
price index (CPI) [39]. The median price ratio was
calculated if a medicine was found in at least three
outlets per sector. An MPR of maximum 4 was con-
sidered as a threshold in this study given the costs at
different stages along the supply chain. For inter-
national comparison of MPR, prices collected in both
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countries were adjusted to purchasing power parity
(PPP) as directed in the WHO/HAI manual [9], con-
version factors were collected from World Bank [27].
Availability is the percentage of facility where a medi-
cine is stocked out of the total number of facilities
per sector. Finally, affordability is expressed in the
number of days’ wage forgone to purchase the
complete treatment of a specific medicine for a
month [9]. The daily wages for the lowest paid un-
skilled government workers (LPGW) were $20 accord-
ing to the laws in Qatar and Lebanon [40, 41]. Only
medicines that were either first choice for each car-
diovascular disease or those that are of national clin-
ical priority were considered for the affordability
calculation. The treatment regimen was based on the
international standard regimen as per WHO [9] and
the new national clinical guidelines launched by the
Ministry of Public Health in Qatar [36].
Data analysis
The Excel workbook available on the HAI website
(www.haiweb.org/medicineprices) was utilized for data
entry and summary. Daily management and review of
collected data were conducted to minimize missing data
and errors.
Ethics
No institutional review board (IRB) approval was re-
quired for the study as confirmed by Qatar University.
Prior to surveying the “public sector”, ethics approval
was received from the Primary Health Care Corporation
(PHCC) in Qatar and a letter directed to the General
Manager of the Ministry of Public Health in Lebanon
seeking approval was accepted and signed. As for the
private sector, a letter of support from Qatar University
was issued and shared with the pharmacy managers
prior to the survey in Qatar. In Lebanon, an
Fig. 1 Refinement process of the surveyed list of medicines
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endorsement phone call from the local study collabor-
ator was made before the visits.
Results
Due to the inherent characteristics of the two coun-
tries surveyed and limited resources, only two differ-
ent sectors were surveyed in Lebanon and three in
Qatar.
Similarly, the number of facilities visited per sector
and per area was limited to one or two upon avail-
ability. A total of 30 outlets were visited, 15 per each
country.
Prices
Price variation in local currency
More price variation incidences were observed in
Lebanon than in Qatar of the same medicine type (either
OB or LPG) between different outlets within and across
sectors. For instance, the MPR of Atorvastatin 20 mg
(LPG) in Qatar demonstrated a slight variation between
27.02 and 30.47, while the MPR values of the LPG
brands in Lebanon varied between 9.96 the lowest and
18.51 the highest. For this same medicine, the median
MPR in Qatar was approximately twice the figure in
Lebanon (29.06 vs. 15.34). The price variation of LPG
was higher than those of OB in line with the multitude
of generic brands for the same medicine found in the
outlets especially in Lebanon. Table 3 demonstrates the
few instances of these variations.
Median price ratio (MPR)
Table 4 illustrates the median MPR for both medicine
types across sectors in Qatar and Lebanon. Medicines
are free-of-charge in the public sector in Lebanon
and only for the Qataris in Qatar. Only the “Public
Sector Patient Prices” in Qatar showed acceptable
MPR with a median CPI-adjusted MPR of 1.44 (0.45–
2.33) and 0.01 (0.01–0.01) for OBs and LPG, respect-
ively. The LPG CPI-adjusted MPR is not representa-
tive of all generics in PHCC since sufficient data was
only available to calculate the median MPR of capto-
pril 50 mg. The median MPR in the private sector
and other sector patient prices were comparable for
each medicine type. However, median MPRs for these
two sectors were significantly higher than those of a
comparative basket purchased from PHCC (Table 5).
Purchasing a comparable basket of medicines from
community pharmacies or from outpatient pharma-
cies, patients would have to pay 13.6 and 14.2 times
the price paid in PHCC. The median MPR of medi-
cines dispensed in the community pharmacies in
Lebanon is 12.37 (IQR = 3.30–32.57) for OB and 5.82
(IQR = 1.85–13.56) for LPG, whereas in Qatar it is
quite comparable with 21.60 (IQR = 6.42–40.43) vs.
26.50 (IQR = 22.70–29.26) for OBs and LPGs respect-
ively (Table 4). It is important to mention that an
MPR of more than 5 for the private sector and more
than two for public sector is considered as a cut-off
values for fairly high prices.
International comparison
After adjusting for purchasing power parity, the median
MPR of medicines (both types) revealed higher price ra-
tio to international reference prices in Qatar than in
Lebanon (Table 6). Table 7 demonstrates few examples
of purchasing power parity (PPP) and consumer price
index (CPI) adjusted-MPR.
Brand premium
Across all four sectors, the MPR of lowest priced ge-
nerics were lower than those of their respective origin-
ator brands (Table 8). With the near absence of LPG in
the public sector in Qatar, the prices of matched LPGs
Table 2 List of medicines surveyed
Medicine name Dosage strength Dosage form Affordability
Acetylsalicylic acid 100 mg cap/tab ✓
Amiodarone 200mg cap/tab ✓
Amlodipine 5 mg cap/tab ✓
Atenolol 50 mg cap/tab
Atenolol (2) 100 mg cap/tab
Atorvastatin 10mg cap/tab
Atorvastatin (2) 20 mg cap/tab ✓
Atorvastatin (3) 40 mg cap/tab
Bisoprolol 5 mg cap/tab ✓
Captopril 25 mg cap/tab
Captopril (2) 50 mg cap/tab
Clopidogrel 75 mg cap/tab ✓
Digoxin 0.25 mg cap/tab ✓
Diltiazem 60mg cap/tab
Enalapril 5 mg cap/tab ✓
Furosemide 40mg cap/tab ✓
Gemfibrozil 600 mg cap/tab
Hydrochlorothiazide 25mg cap/tab ✓
Isosorbide dinitrate 5 mg cap/tab
Losartan 50mg cap/tab
Methyldopa 250mg cap/tab
Propranolol 10 mg cap/tab
Propranolol (2) 40 mg cap/tab
Simvastatin 10mg cap/tab
Simvastatin (2) 20 mg cap/tab ✓
Spironolactone 25mg cap/tab ✓
Verapamil 80 mg cap/tab ✓
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were almost 39 and 34% lower than their corresponding
originators in the two private sectors surveyed. In
Lebanon, for the matched pairs of medicines found (13
medicines), the price of LPGs was 65% less than their re-
spective OBs (Table 8).
As reported per the Qatari and Lebanese pharmaceut-
ical pricing guidelines [19, 20], generic medicines should
be priced at least 35 and 30% less than the originator
brands in Qatar and Lebanon, respectively. By referring
to the brand premium observed in our survey (Table 8),
prices of LPG are in line with the regulations in both
countries.
Availability
A high variability in the mean availability of origin-
ator brands and lowest priced generics were detected
especially in the public primary health centers in both
countries (Table 9). The mean availability of generics
in Qatar is low with its highest mean (SD) of 29.60%
(37.10%) observed in the community pharmacies. In
the same context, Qatar relies mainly on OB in its
PHCC centers where mean availability (SD) of OB
was 82.20% (27.90%) in the 5 outlets visited with a
minimal supply of LPG 5.90% (15.50%). PHC in
Lebanon are only dispensing generic essential medi-
cines, nevertheless, the availability was critically low
with only 46.90% (36.10%). The mean availability of
OB and LPG medicines in the community pharmacies
in Lebanon was higher than the two private sectors
in Qatar. In Lebanon, patients were more likely to
face low availability of essential CVD medicines in
the public sector in comparison to the private
pharmacies.
Affordability
Affordability was calculated for those medicines avail-
able in three or more outlets per sector. Medicines
were affordable in the public primary healthcare centers
in Qatar (Table 10). While nine out of thirteen medi-
cines were at 1 days’ wage or less in all private sector
outlets surveyed in both countries, enalapril (antihyper-
tensive medicine), simvastatin and atorvastatin (lipid-
lowering agents), and clopidogrel (antithrombotic)
monthly regimen exceeded the threshold. The origin-
ator brand of clopidogrel was the most burdening
medicine in both countries as LPGWs have to forgo 4.2
and 2.5 days’ wages in Qatar and Lebanon, respectively,
in order to purchase their monthly dosage from the pri-
vate sectors.
For originator brand medicines that impose high bur-
den on LPGW, cheap affordable generics existed. For in-
stance, by substituting originator branded clopidogrel by
its generic equivalent, LPGW could have saved 1.6 days’
wages in Qatar and Lebanon respectively.
Discussion
This study was planned to assess the price, availability
and affordability of essential cardiovascular medicines
within and across Qatar and Lebanon. This study found
out that the medicine price was more uniform across
the same sector in Qatar than in Lebanon. In the Qatari
public sector, medicines were priced lower than the
international reference prices. However, the prices of
medicines in the private sector were higher than the
international reference prices in both countries. The
MPR of OBs and LPGs in the private sectors in Qatar
(private sector, and other sector surveyed) were up to
Table 3 MPR percentiles variation in the private sectors for both medicine types in Qatar and Lebanon
Country/sector Medicine and product type Median MPR 25th percentile 75th percentile
Qatar/ Other Sector Acetylsalicylic acid- OB 12.07 11.91 12.07
Atorvastatin 20 mg- OB 24.11 24.11 24.11
Atorvastatin 20 mg- LPG 29.06 27.02 30.47
Lebanon/ Private Sector Atorvastatin 20 mg- LPG 15.34 9.96 18.51
Hydrochlorothiazide 25 mg- OB 14.25 13.43 15.07
Captopril 50 mg- OB 3.83 3.66 3.83
Table 4 Median CPI-adjusted MPR of originator and generic brands in all sectors surveyed in Qatar and Lebanon
Qatar Lebanon
Public (n = 5) Private (n = 6) Other (n = 4) Private (n = 6)
OB LPG OB LPG OB LPG OB LPG
Median MPR (IQRa) 1.44 (0.45–2.33) 0.01 (0.01–0.01) 21.60 (6.42–40.43) 26.50 (22.70–29.26) 26.71 (14.44–46.04) 29.52 (25.11–33.81) 12.37 (3.30–32.57) 5.82 (1.85–13.56)
Min MPR 0.09 0.01 0.72 0.40 0.72 13.28 0.52 0.32
Max MPR 9.68 0.01 67.73 44.10 67.73 44.10 59.73 41.13
Medicines included 23 1 19 9 14 4 20 17
Note: Min minimum, Max maximum
aInterquartile range
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two and five times higher than those in Lebanon, re-
spectively. In terms of availability, only the public sec-
tor in Qatar met the WHO target for OB CVD
medicines. Medicines in the public sector were dis-
pensed free-of-charge for beneficiaries of the National
Chronic Drugs Program in Lebanon and for Qatari na-
tionals in Qatar and were all affordable for non-Qataris
in the primary health care centers (public sector). In
the private sectors surveyed, there were medicines con-
sidered unaffordable. In cases where the OB was not af-
fordable, a less expensive generic substitute was
available. The higher occurrence of the price variations
of the originator brands observed in Lebanon could be
due to the fact that the medicine price may change
every 2 weeks according to the bi-monthly index re-
leased by the MoPH to all warehouses and pharmaceut-
ical outlets. These indices adjust prices based on
foreign currency exchange rates fluctuations [17]. Small
variations are commonly encountered [42] even under
strict pharmaceutical pricing and monitoring regulation
as in Saudi Arabia [43], Iran [44] and Lebanon in 2013
[17]. As for LPG’ price variations, this could be attrib-
uted to the fact that several generic brands of the same
active ingredient exist in the market as observed in
Saudi Arabia in 2015 [43], Lebanon 2013 [17] and Iran
2014 [44].
The median MPR of OB prices paid by the non-Qatari
residents in the public sector were the lowest when
compared to those in countries of any income level in-
cluding Sri Lanka [45], Iran [44], and 11 other Asia Pa-
cific countries [46]. The significant difference in the
prices paid by patients between the public and private
sectors in Qatar demonstrated the Qatari vision for a
subsidized public healthcare system that is of inter-
national standard and affordable to all. The high ratios
to IRP in community pharmacies in Qatar (21.6 for OB
and 26.52 times the IRP for LPG) were also significantly
higher when compared to Saudi Arabia (6.66, 8.88 times
the IRP) [43] and Iran (3.62, 1.21 times the IRP) [44].
Given that Saudi Arabia and Qatar are utilizing the
same pharmaceutical pricing guidelines and bulk pro-
curement for the private sector, the difference in MPR
could be related to the higher and linear mark-up
schemes applied in Qatar compared to a regressive
mark-up in Saudi Arabia. In Lebanon, medicine prices
were reduced by the end of 2015, the median MPR of
OB increased in 2016 by 2.5% (12.36 vs. 12.06 times the
IRP). This can be due to the fact that the 2013 WHO/
HAI survey included a different basket of chronic and
acute diseases essential medicines whose prices may
have affected the overall median MPR [17]. As for ge-
nerics, their prices decreased by 18.2% (5.48 vs. 6.7 times
the IRP and close to threshold) after the pricing mech-
anism of generic medicines was reevaluated, however it
is still significantly higher than Iran (1.21 times the IRP)
most likely due to more developed domestic generic
manufacturing in Iran [47, 48].
Accounting for the difference in economic strength
[27, 49] did not reduce the gap of difference in price ob-
served between Qatar and Lebanon which is in line with
other studies that showed the absence of any link be-
tween the level of income and the prices of medicines in
a country [50–52] except for Schweitzer and Comanor
study [53]. The price difference between low-middle-
income countries (LMIC) or developing countries on
one hand and industrialized countries on the other hand
could be due to differential pricing [54, 55].
Given that the adjustments to prices applied in this
study did not provide possible explanation for the gap in
prices between Qatar and Lebanon, further investigation
of the landed price2 and the pricing mechanisms is
needed in the future to provide answers [9].
With the international WHO target to achieve more
than 80% availability of affordable essential generic med-
icines in at least the public sector by 2030 [1], a slight
improvement of the availability of generic essential CVD
medicines was observed in the Lebanese public sector in
comparison to the year 2013 (46.9% in 2016 vs. 42% in
2013). However, this availability is lower compared to
the upper-middle income countries (UMIC) average as
per Ewen et al. study [1]. This discrepancy may be re-
lated to the difference in the medicine basket surveyed.
The absence of OB of essential CVD medicines in the
public sector in Lebanon is in line with what Ewen et al.
(2017) demonstrated in their secondary study of WHO/
Table 5 Comparison of the median MPR between a common basket of matched pair of medicines across sectors in Qatar
Public Private Public Other Private Other
Number of matched medicines 17 14 14 (OB)
4 (LPG)
MPR - OB 1.77 24.11 1.89 26.71 26.71 26.71
MPR - LPG 27.92 29.72
% Difference 1264.90% 1316.90% 0.00% OB/ 6.40% LPG
2Landed price is the second out of five price components. It is the
price of a shipped medicine that had cleared customs and import
duties , transported to wholesalers or importer. It is the cost of the
procurement process.
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HAI between 2008 and 2015 for UMICs surveyed in
which Lebanon was included alongside Iran, Colombia,
Ecuador, Mauritius, Mexico, and Brazil [1].
The subsidy of the public sector in Qatar was also
reflected in the predominant availability of originator
brands of the surveyed medicines. This availability
exceeded the WHO target (82.2%) [1] and is signifi-
cantly higher than OB NCD medicines in the same
sector in Saudi Arabia (82.2% vs. 22.3%) [43] and the
generic medicines availability in the public sector in
Iran (75.2%) [44], where pharmaceutical pricing pol-
icies were enacted to control and challenge the OBs
entry into the market while generics manufacturing is
subsidized and their prices are controlled and com-
petitive [47, 48]. The low availability of generic medi-
cine in all sectors in Qatar may be related to
consumer preferences for OBs [56, 57]. The unavail-
ability of any type of digoxin, diltiazem, amiodarone
or isosorbide dinitrate in the private sector may be
related to their usage restriction in community phar-
macies and to the structure of the healthcare system
in Qatar where private cardiology medical services in
Qatar are generally limited and mostly available in
major hospitals in the capital city.
Our results showed that medicines in the public
sector in Qatar were affordable to LPGW. Compared
to the private sector in Saudi Arabia, purchasing of
medicines by non-nationals in the private sector in
Qatar is more affordable when comparing all types of
amlodipine and clopidogrel [43]. In Lebanon, despite
the fact that the OB medicines exceeded the one-day’
wage threshold in 2016, the few common essential
CVD medicines surveyed in Lebanon (clopidogrel,
amlodipine, amiodarone, hydrochlorothiazide, simva-
statin and atorvastatin) became more affordable in
2016 compared to 2013 [17] and were more afford-
able than in Saudi Arabia (2015) for any type [43],
and more affordable than the OBs in Iran (2014) [44].
Once more, the pharmaceutical pricing policy of OBs
in Iran may have resulted in more expensive OB
medicines in comparison to Lebanon.
Nevertheless, the official LPGW salaries adopted for
calculation in both Qatar and Lebanon omit a sub-
stantial portion of the local population. In Qatar, out
of a population of circa 2.58 million, around one mil-
lion are blue-collar laborers employed in the private
sector that are paid almost half of the LPGW salary
adopted in our study. In order to calculate affordabil-
ity for these workers, we would need to almost
double the number of days’ wages required to pur-
chase a treatment course. Similarly, according to the
2016 UNDP report on Lebanon, 27% of the popula-
tion is living under the poverty line and earning less
than $4 per day [58]. Moreover, as of 2011, there
were only 162,016 out of registered beneficiaries
under the National Chronic Drug Program in
Lebanon who are eligible to obtain free medicines in
primary healthcare centers [17]. Overall, roughly half
of the Lebanese population has some form of health
coverage (public and private) [17], while in Qatar all
residents are eligible for subsidized healthcare services
and medication through the Primary Health Center
Corporation (PHCC) and Hamad Medical Center
(HMC). Considering the low availability of medicines
in the public sector in Lebanon, most of the patients
with chronic diseases are purchasing their medicines
from the private sector and thus paying out-of-pocket
for CVD medicines. It is worth mentioning that pa-
tients with pre-existing conditions or chronic diseases
can sometimes find it difficult to obtain private
Table 8 MPR of comparable basket of matched OB and LPG pair medicines found per sector
Qatar Lebanon
Private Other Private
OB LPG Brand
prem.
OB LPG Brand
prem.
OB LPG Brand
prem.9 9 4 4 13 13
Median MPR 43.61 26.52 1.64 45.23 29.72 1.52 21.76 7.64 2.85
25%ile MPR 36.73 22.70 1.62 38.73 25.11 1.54 4.81 2.15 2.24
75%ile MPR 48.28 29.26 1.65 52.07 33.81 1.54 35.15 15.34 2.29
Min MPR 0.72 0.40 1.80 24.11 13.28 1.82 0.68 0.32 2.13
Max MPR 67.73 44.10 1.54 67.73 44.10 1.54 59.73 41.13 1.45
Note: Min minimum, Max maximum, Prem. premium
Table 7 PPP and CPI-adjusted MPR of individual medicines in
community pharmacy
Medicine Qatar Lebanon
OB LPG OB LPG
Clopidogrel 75 mg 70.34 43.46 37.61 13.72
Atorvastatin 20 mg 89.72 48.76 60.75 26.52
Amlodipine 5 mg 129.71 84.45 54.55 44.37
Acetylsalicylic acid 100 mg 23.12 18.15 12.94
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insurance as insurers can significantly increase pre-
miums and deductibles or refuse coverage to such pa-
tients. It is important to note that most CVD cases
require multidrug regimens [2], hence the affordability
of a treatment plan would depend on the sum of
prices of all drugs prescribed to a patient. The study
findings provide several possible policy actions that
could be adopted to improve sustainable access to af-
fordable medicines.
Such studies provide valuable advocacy messages for
policymakers, pharmaceutical industries, regulators,
prescribers and patients if well shared and delivered
in a timely manner. Generic uptake in Qatar is still at
its infancy, and more effort could be made to pro-
mote the acceptance of generic brands among pre-
scribers, pharmacists and patients. Pharmacist should
be legally permitted to substitute generic brands for
OB. As such, an amendment to the pharmacy practice
law enacted in 1980 must be considered. Moreover,
facilitating the regulatory process involved in the
registration of prequalified quality generic and en-
couraging the local manufacturing of such medicines
are highly recommended. This would result in the
optimization of the drug budget in the Qatari public
sector by procuring more good quality generic medi-
cines and by providing a cheaper alternative for pa-
tients in the private sector.
The price of medicines in the private sector in Qatar
must be reconsidered for further price reduction and the
linear mark-up added to the supply chain should be re-
placed by a regressive scheme. Several policy actions could
be implemented in Lebanon as well. First, MoPH
should prioritize the pharmaceutical budget to ensure
that all essential medicines on the national EML are
available in the public sector. This can increase the
availability of medicines in the public sector and de-
crease the out-of-pocket spending on pharmaceuticals
in the private sector. The coverage of NCD patients
under the National Chronic Drugs Program must also
be expanded to include the growing segment of the
population below the poverty line. The quality of the
available generic medicines especially in the private
sector in Lebanon should be rigorously assured, and
more emphasis should be put into the regulatory
Table 10 Affordability in number of days’ wages needed to purchase standard treatment
Days’ wages needed to purchase a 30 days’ treatment
Qatar Lebanon
PHCC Community pharmacies Private clinics/hospitals Community pharmacies
Bisoprolol 5 mg × 60 0.1 OB 0.9 OB 0.9 OB 1 OB/ 0.4 LPG
Digoxin 0.25 mg × 30 0 OB 0 OB
Verapamil 80 mg × 90 0.2 OB 1 OB
Amiodarone 200mg × 30 0.1 OB 0.3 OB / 0.2 LPG
Amlodipine 5 mg × 30 0.1 OB 0.9 OB / 0.6 LPG 0.9 OB / 0.6 LPG 0.4 OB / 0.4 LPG
Enalapril 5 mg × 120 0.1 OB 3 OB / 1.6 LPG 3 OB
Hydrochlorothiazide 25 mg × 30 0 OB 0.3 OB 0.3 OB 0.2 OB
Furosemide 40mg × 30 0 OB 0.4 OB 0.4 OB 0.4 OB
Spironolactone 25mg × 30 0.4 OB 0.2 OB
Acetylsalicylic acid 100 mg × 30 0 OB 0.1 OB 0.1 OB 0.1 OB / 0.1 LPG
Clopidogrel 75 mg × 30 0.4 OB 4.2 OB / 2.6 LPG 4.2 OB 2.5 OB / 0.9 LPG
Simvastatin 20mg × 30 0.1 OB 1.4 OB / 1.1 LPG 1.4 OB / 0.2 LPG
Atorvastatin 20 mg × 30 0.3 OB 3.1 OB / 1.7 LPG 3.1 OB / 1.9 LPG 2.3 OB / 1 LPG
Table 9 Mean availability (in percent) of cardiovascular diseases medicines in sectors surveyed in Qatar and Lebanon
Qatar Lebanon
Public (n = 5) Private (n = 6) Other (n = 4) Public (n = 9) Private (n = 6)
OB LPG OB LPG OB LPG OB LPG OB LPG
Mean Avail. 82.20 5.90 64.80 29.60 54.60 25.00 0.00 46.90 69.80 58.60
SD 27.90 15.50 37.90 37.10 40.50 34.70 0.00 36.10 32.70 39.90
Note: Avail. availability, SD standard deviation
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process prior to registration to avoid substandard and
counterfeit medicines.
In light of the recent regional blockade on Qatar, it
would be relevant to reconduct the survey to measure
the efficiency of measures undertaken by local author-
ities to overcome the situation. More frequent surveys of
most common communicable and non-communicable
diseases medicines and their price components are
needed. The data on medicine price collected in our sur-
vey could be used by other methods that measure af-
fordability such as impoverishing and catastrophic
effects.
The design of the survey is cross-sectional while in
countries where pharmaceutical policies and pricing are
amended over time, changes may be better detected by
longitudinal studies. Strategic and logistic limitation may
have affected the findings. Thus, two limitations arose; a
sample size that might have affected the external validity
of the study findings and the fact that no quality analysis
of medicines was conducted. Furthermore, the afford-
ability may have been overestimated by neglecting the
multidrug regimens fact and other healthcare expenses.
Finally, including only essential medicines in the sur-
veyed list may have been restrictive especially for the
private sector.
To the best of our knowledge, this study is the first in
Qatar and the fifth in a high-income country (HIC). Sec-
ond, the medicines surveyed are of global and national
priority and are proven to be safe and cost-effective. Our
findings could also be used as indicators for the assess-
ment of millennium development targets and other
NCD indicators. Key policy decisions should be imple-
mented to improve access to medicines in both
countries.
Conclusion
By using a variant of the WHO/HAI methodology, we
quantitatively evaluated the medicine prices in com-
parison to international reference prices, as well as
their availability and affordability in both Qatar and
Lebanon. Pharmaceutical pricing policies were also
summarized for comparative purposes. In summary,
data revealed that medicine prices were more uniform
across the same sector in Qatar than in Lebanon. In
general, the price of originator brands and lowest
priced generics in Qatar were higher than those in
Lebanon. Across all four sectors, the MPR of LPGs
were lower than those of their respective OBs. Gener-
ally, the studied medicines in the public sector in
both countries were either free-of-charge or afford-
able. In the private sectors surveyed, some medicines
were consistently unaffordable. Even in cases where
the OB was not affordable, a less expensive generic
substitute was available. In terms of availability of
medicines, only the public sector in Qatar met the
WHO recommendation. In addition, medicines were
more available in the private sector in Lebanon than
in Qatar. The originator brand availability in the pub-
lic sector in Qatar exceeded the WHO recommenda-
tion. Except for the public sector in Qatar, both
countries fall short of the Sustainable Development
Goals, and more efforts should be undertaken to
achieve these goals.
Appendix
Abbreviations
CPI: Consumer price index; CVD: Cardiovascular diseases; EML: Essential
medicine list; EMRO: Eastern Mediterranean Regional Office of the WHO;
HIC: High-income country; HMC: Hamad Medical Center; HMC: Hamad
Medical Corporation; IQR: Interquartile range; IRB: Institutional review board;
IRP: International reference price; LMIC: Low-middle-income countries;
LPG: Lowest-priced equivalent generic; LPGW: Lowest paid unskilled
government workers; MPR: Median price ratio; MSH: Management Sciences
for Health; NCD: Non-communicable diseases; NGO: Nongovernmental
Table 12 Generic brands pricing strategies in comparison to OB
in Lebanon
Lebanon
Generics with
available OB in
the market
-30% of the OB
price
Generics with
no available OB
in the market
Category 1 Country of origin:
US, UK, Canada, France,
Austria, Belgium,
Sweden, Germany,
Switzerland, Ireland,
Norway, Denmark, Italy,
Spain, Netherlands,
Finland, Japan, and
Australia
Price for the first three
generics in each category
is set based on Price
Certificate presented at
registration. Within 3
months of a new generic
being registered, the
price is revised to be the
average price of all
generics within the
category. Price is also
revised in case of price
variation of any of the
generics in the category.
Category 2 All other countries
Locally
packaged
generics (under
license)
Price depends on
the ex-factory
price in the
country of origin
In both cases, price should be 30% less than OB
Locally
manufactured
generics
Price depends on
local ex-factory
price
Table 11 Generic brands pricing strategies in comparison to OB
in Qatar
Qatar
First generic -35% of the OB price
Second until fourth chronologically
registered generics
-10% from the last registered
generic
Fifth generic onward Same price as the fourth
registered generic in the market
Locally manufactured under licensed
or locally packaged generics
Same pricing mechanism as
imported generics
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organizations; OB: Originator brand; PHCC: Primary Health Care Corporation;
PPP: Purchasing power parity; SD: Standard deviation; UMIC: Upper-middle
income country; WHO/HAI: World Health Organization and Health Action
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